- Home
- VRNA vs CFR Comparison
VRNA vs CFR Comparison
Compare VRNA & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CFR
- Stock Information
- Founded
- VRNA 2005
- CFR 1868
- Country
- VRNA United Kingdom
- CFR United States
- Employees
- VRNA N/A
- CFR N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CFR Major Banks
- Sector
- VRNA Health Care
- CFR Finance
- Exchange
- VRNA Nasdaq
- CFR Nasdaq
- Market Cap
- VRNA 8.3B
- CFR 7.9B
- IPO Year
- VRNA 2017
- CFR N/A
- Fundamental
- Price
- VRNA $104.83
- CFR $137.38
- Analyst Decision
- VRNA Buy
- CFR Hold
- Analyst Count
- VRNA 11
- CFR 14
- Target Price
- VRNA $112.40
- CFR $136.50
- AVG Volume (30 Days)
- VRNA 5.5M
- CFR 338.9K
- Earning Date
- VRNA 08-07-2025
- CFR 07-31-2025
- Dividend Yield
- VRNA N/A
- CFR 2.91%
- EPS Growth
- VRNA N/A
- CFR 7.71
- EPS
- VRNA N/A
- CFR 9.11
- Revenue
- VRNA $118,535,000.00
- CFR $2,038,108,000.00
- Revenue This Year
- VRNA $891.79
- CFR $12.87
- Revenue Next Year
- VRNA $78.94
- CFR $3.99
- P/E Ratio
- VRNA N/A
- CFR $14.97
- Revenue Growth
- VRNA N/A
- CFR 5.45
- 52 Week Low
- VRNA $17.96
- CFR $100.31
- 52 Week High
- VRNA $104.99
- CFR $147.64
- Technical
- Relative Strength Index (RSI)
- VRNA 70.87
- CFR 69.97
- Support Level
- VRNA $86.63
- CFR $135.95
- Resistance Level
- VRNA $104.99
- CFR $139.34
- Average True Range (ATR)
- VRNA 2.73
- CFR 2.49
- MACD
- VRNA 0.50
- CFR 0.85
- Stochastic Oscillator
- VRNA 99.24
- CFR 84.82
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.